<DOC>
	<DOCNO>NCT00000638</DOCNO>
	<brief_summary>To evaluate compare safety effectiveness one-year course isoniazid ( INH ) versus two-month course rifampin plus pyrazinamide prevention reactivation tuberculosis individual infect HIV latent ( inactive ) Mycobacterium tuberculosis . Current guideline American Thoracic Society Centers Disease Control recommend 6 12 month INH PPD ( purify protein derivative ) -positive individual . Although effectiveness treatment know HIV-infected individual , several study use INH prevent tuberculosis presumably normal host show 60 80 percent effectiveness . Problems treatment include compliance , adverse reaction , possibility prevent disease due tuberculosis organism resistant INH . A two-month preventive treatment plan help increase compliance . In addition , use two drug ( rifampin / pyrazinamide ) may help overcome problem drug resistance . If study show equal great effectiveness two-month rifampin / pyrazinamide treatment , could alter approach tuberculosis prevention HIV-positive HIV-negative individual .</brief_summary>
	<brief_title>Preventive Treatment Against Tuberculosis ( TB ) Patients With Human Immunodeficiency Virus ( HIV ) Infection Confirmed Latent Tuberculous Infection</brief_title>
	<detailed_description>Current guideline American Thoracic Society Centers Disease Control recommend 6 12 month INH PPD ( purify protein derivative ) -positive individual . Although effectiveness treatment know HIV-infected individual , several study use INH prevent tuberculosis presumably normal host show 60 80 percent effectiveness . Problems treatment include compliance , adverse reaction , possibility prevent disease due tuberculosis organism resistant INH . A two-month preventive treatment plan help increase compliance . In addition , use two drug ( rifampin / pyrazinamide ) may help overcome problem drug resistance . If study show equal great effectiveness two-month rifampin / pyrazinamide treatment , could alter approach tuberculosis prevention HIV-positive HIV-negative individual . Patients chosen random selection process either INH rifampin / pyrazinamide arm dose . Patients INH arm receive INH plus vitamin B6 ( pyridoxine hydrochloride ) daily 12 month . Patients arm receive rifampin plus pyrazinamide 60 day . Dosage rifampin pyrazinamide depends weight patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<mesh_term>Vitamin B 6</mesh_term>
	<mesh_term>Pyridoxal</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral treatment . Pneumocystis carinii pneumonia prophylaxis . Treatment acute opportunistic infection . Patients must : HIV infection . Current documented history positive PPD skin test . Life expectancy least 6 month , physician 's opinion , patient reasonable chance survival end study . Allowed : Participation clinical trial long potential activity study drug Mycobacterium tuberculosis ( MTb ) , additive toxicity study agent , know possible drug interaction study drug . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Current active clinical tuberculosis , confirm suspect . History sensitivity / intolerance study medication . Evidence peripheral neuropathy , i.e. , sign symptom paresis , paresthesia , neuromotor abnormality , neurosensory deficit grade 3 worse . Unwilling unable current therapy and/or concomitant medication change avoid serious interaction study medication . Acute hepatitis . Unable comply followup requirement protocol . Concurrent Medication : Excluded : Treatment quinolones , fluoroquinolones , aminoglycosides , agent activity Mycobacterium tuberculosis . Excluded ongoing ( i.e. , continuous , chronic and/or recur ) treatment : Aminoglycosides amikacin , aminosalicylic acid salt ( PAS ) , capreomycin , clofazimine , cycloserine , ethambutol , ethionamide , isoniazid ( INH ) randomize rifampin/pyrazinamide arm study , kanamycin , pyrazinamide randomize INH arm study , quinolones fluoroquinolones , i.e. , rifabutin , rifampin ( randomize INH arm study ) , ciprofloxacin , levofloxacin , ofloxacin , streptomycin , thiacetazone . Prior Medication : Excluded : More 2 month continuous treatment , documentation positive PPD skin test , agent know potential antituberculous activity antimycobacterial medication &gt; 1 month . Patients may follow prior condition : History sensitivity / intolerance study medication . Unwilling unable comply followup requirement protocol .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>Isoniazid</keyword>
	<keyword>Mycobacterium tuberculosis</keyword>
	<keyword>Pyrazinamide</keyword>
	<keyword>Pyridoxine</keyword>
	<keyword>Rifampin</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antitubercular Agents</keyword>
	<keyword>AIDS-Related Complex</keyword>
</DOC>